World Class, Customized Medicinal Cannabis to use Genetic-based Tech
LEAMINGTON, Ontario, Feb. 1, 2016 /Weed Wire/ — Aphria Inc (TSX VENTURE:APH), one of Canada’s leading large scale producers of medical-grade cannabis, partners with pioneering ESEV Genetics to develop and bring to market the highest quality strains of cannabis available to treat a range of medical conditions.
ESEV Genetics creates cutting-edge genetic tools and a science-based platform for the enhancement of cannabis breeding to cannabis farms around the world. Headquartered in NY, ESEV’s R&D is centred in Israel, cooperating with the country’s top scientific institutions who have been researching medicinal cannabis for fifty years and legally treating patients with it for the past ten. Israel’s open source medical records system also helps researchers and medical prescribers understand the effects of cannabis on conditions.
ESEV is one of the first companies to apply next-generation genetics-based technologies and techniques to breeding cannabis, utilizing DNA marker tools to create highly accurate, custom made and stable strains. This advanced methodology is far more cost effective, producing greater yield per area and per time unit.
Our primary commitment is to grow, harvest and deliver a consistent medicine to patients,” said Vic Neufeld, CEO, Aphria Inc. “Using ESEV genetic breeding technologies will allow us to further enhance quality control, increase production yield and maintain our low cost producer status. We are excited and eager to expand our commercial agri-business best practices in partnership with ESEV.”
Aphria has one of the fastest seed-to-sale timelines amongst Canadian licensed producers and has established a reputation as a leading low cost medical cannabis producer within the investor community. With the new partnership, Aphria will apply the same type of innovative genetic-based breeding technologies used to commercialize greenhouse flowers, crops and tomatoes to greenhouse medical cannabis.
“Aphria’s advanced cultivation methods and proven track record as a leading LP in Canada together with our advanced genetic technologies and experience will set the standard in the Canadian market for premium medical-cannabis varieties,” said Golan Vaknin, CEO, ESEV. “Unlike many other players that genetically modify breeds, our techniques have proven to be the most precise, consistent and cost-effective.”
For all press enquiries, please contact:
Tel: +44 7771 926726
Aphria Inc., a company continued under the laws of the Province of Ontario and based in Leamington, Ontario, is in the business of producing, supplying and selling medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). Under the MMPR, Health Canada is responsible for the oversight of commercial medical marijuana growers such as Aphria. Aphria’s common shares are listed on the TSX Venture Exchange under the ticker symbol “APH”. www.aphria.com
ESEV Genetics develops cutting-edge genetic tools and technologies for cannabis breeding. Established in 2014, the company is based in the US and Israel. The team has been accredited by the agricultural industry for utilising these breeding techniques to develop and commercialise tomatoes, rice and maize.